This company is no longer active
5YX Stock Overview
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Angion Biomedica Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.05 |
| 52 Week High | US$17.10 |
| 52 Week Low | US$6.00 |
| Beta | 0.60 |
| 1 Month Change | 50.83% |
| 3 Month Change | n/a |
| 1 Year Change | -38.85% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5YX | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 16.0% | 1.6% | 0.05% |
| 1Y | -38.9% | -14.7% | 9.4% |
Return vs Industry: 5YX underperformed the German Pharmaceuticals industry which returned -12.6% over the past year.
Return vs Market: 5YX underperformed the German Market which returned -7.6% over the past year.
Price Volatility
| 5YX volatility | |
|---|---|
| 5YX Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5YX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 5YX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 8 | Jay Venkatesan | www.angion.com |
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid.
Angion Biomedica Corp. Fundamentals Summary
| 5YX fundamental statistics | |
|---|---|
| Market cap | €27.99m |
| Earnings (TTM) | -€27.05m |
| Revenue (TTM) | €606.90k |
46.1x
P/S Ratio-1.0x
P/E RatioIs 5YX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5YX income statement (TTM) | |
|---|---|
| Revenue | US$653.00k |
| Cost of Revenue | US$6.76m |
| Gross Profit | -US$6.11m |
| Other Expenses | US$23.00m |
| Earnings | -US$29.10m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | -935.07% |
| Net Profit Margin | -4,456.97% |
| Debt/Equity Ratio | 0% |
How did 5YX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/02 07:28 |
| End of Day Share Price | 2023/06/01 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Angion Biomedica Corp. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Justin Kim | Oppenheimer & Co. Inc. |
| Annabel Samimy | Stifel, Equities Research |